Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-822-9_14

Chapter 14: Commercialization and Market Trends in Nano Cardio-Therapeutics

Vasanthi A V[1*], Morziul Haque[1], Aarzoo Ali[2], Varad Anand Raut[3], Akhilesh Madhav Bhede[4], Akansha Bisht[5]

[1,2]Research Scholar, Department of Pharmacy, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Tarnaka, Secunderabad, Telangana, India – 500017*
[1]Department of Pharmacy, University Institute of Pharma Sciences, Chandigarh University, Punjab, 140413, India,
[3]Oyester Institute of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, 431001, India.
[4]Government College of Pharmacy, Chhatrapati Sambhajinagar - Osmanpura road, Chhatrapati Sambhajinagar, India- 431005,
[5]Department of Pharmacy, Jagannath University, Chaksu Bypass, Jaipur, Rajasthan, India.
Corresponding Author*
Vasanthi A V
Email ID: *vasanthi20230104@gmail.com*

Abstract

This chapter explores the commercialisation and market pattern of nano cardio-therapeutics, the interest of integrating nano cardio-therapeutics with nutraceuticals and naturopathic therapies in order to prevent cardiovascular diseases (CVD). It starts by giving a definition and a historical development, which underlines its relevance due to the burden of CVD in the world, as over 500 million people are affected each year. The global nanomedicine market worth around USD 265-294 billion in 2025 will be divided into drug delivery systems, diagnostics and therapeutics, with forecast revenues of USD 632-779 billion by 2034 at a rate of 10-12 percent CAGR. Regional summary reveals the command by North America and fast expansion of Asia-Pacific region due to an increase in the incidences of CVD and the demand of selective therapeutics. Meaningful growth opportunities are supported by technological progress in personalized medicine and nano-nutraceuticals such as curcumin and resveratrol formulations to help address oxidative stress. Ways of commercialization, from preclinical to market are discussed, with references to the public-private partnership and to particular examples, e.g. the inclusion of liposomal systems. Regulatory programs (FDA, EMA), safety issues, such as biocompatibility, ethical issues, and on accessibility, in naturopathic care, are discussed. Technical, economical and integration barriers are discussed with major players such as Bristol-Myers Squibb, Novartis and Pfizer. Case studies provide examples of success and failure, and future outlooks take into account intelligent nano-systems, integration of AI and growing into developing countries. The chapter sums up with policy recommendations aimed to promote innovation, in turn, guaranteeing fair naturopathic CVD services. They became more like the creatures they observed: animals well-qualified to survive in the natural world.

Keywords: *Nano Cardio-Therapeutics; Commercialisation; Market Trends; Nanomedicine; cardiovascular disease*

1. INTRODUCTION TO NANO CARDIO-NUTRACEUTICALS

1.1 Overview of Nano Cardio-Nutraceuticals in Cardiovascular Care

Cardiovascular diseases (CVDs) serve as the primary reason for worldwide health problems and death because approximately 17.9 million people die each year and experts expect this figure to reach 23.6 million by 2030. The standard treatment methods for medical conditions through traditional therapies face three main difficulties because they cannot be taken orally and they lack targeted treatment and they cause undesired reactions. Nano chondro-nutraceuticals come into the scene as a potential such drugs where nanotechnology, in this case is combined with nutraceuticals - bioeffectors derived as natural substances such as plant, herbs and diet supplements to exert a beneficial impact on the heart condition. These formulations use nanoscale carriers (also 1-100nm) to enclose, protect, and deliver nutraceuticals directly to the affected cardiac tissues, overcoming challenges such as rapid degradation, low solubility as well as inefficient cellular uptake. Nano cardio-nutraceuticals denote the combination of naturopathic guidance with extraordinary engineering, in which nutraceuticals, including polyphenols (e.g., resveratrol, curcumin), flavonoid (e.g., quercetin), omega-3 fatty acids, and herbal extracts (e.g., ginsenosides of ginseng or honokiol of Magnolia bark) are restructure to nanoparticles, such as liposomes, polymeric nanoparticles, nano-emulsions, This mechanism enhances the intrinsic cardio-protective actions of such compounds such as antioxidants, anti-inflammatory, lipid-lowering, and enhancement of the endothelial function. As an example, in atherosclerosis, one of the major antecedents of myocardial infarction and stroke, plaque locations associated with atherosclerosis can be targeted using nutraceuticals nano-encapsulated to induce cholesterol efflux, inhibit oxidative stress, and stabilize lesions at risk (Omidian, Babanejad, & Cubeddu, 2023).

A case in point is using MSNPs loaded with honokiol, which block the growth of the vascular smooth muscle and prevent an increase in intimal thickening during the preclinical models of restenosis post balloon injury. In the treatment of myocardial infarction, mitochondrial lipid-polymer hybrid particles, developed as a mitochondrion target, incorporated with natural substances, such as calycosin and tanshinone exhibit enhanced cardiac fate, reducing infarct size and disease-modifying impaired myocardial dynamics due to the alleviation of ischemia-reperfusion injuries. Likewise, nanoparticles with the surface covered with platelet membranes containing selenium and ginsenoside Rb1 have been found to be effective in reversing atherosclerotic plaques by controlling the inflammation and oxidation pathways. Beyond increasing bioavailability, often by many folds, these systems can also be stimuli-responsible in delivery, in higher vascular inflammation contexts can be induced by pH- or by enzyme-3-ppt iron responsive delivery. The cardio-nutraceutical nano therapeutics translate to other presentations of CVDs such as: thrombosis, arrhythmia, and hypertension. In the case of thrombosis, niosomal vesicles or von Willebrand factor-functionalized nanoparticles are used to initiate targeted thrombolysis to reduce hemorrhagic risk using nutraceutical adjuncts such as docosahexaenoic acid. Nano-lipid carriers have also been found to enhance the delivery of antiarrhythmic herbal derivatives including Guanfu base A in arrhythmia, increasing heart specificity and circulation time. Altogether, these technologies correspond to a swing towards personalized, preventive cardiology, in which nano-enabled nutraceuticals are used to promote holistic, multisystem disease etiological management at a molecular scale. With these advancements there are still issues, such as that it is cumbersome to scale up production, that there may be long-term biocompatibility, and that nanotoxicity can occur. The focus is on preclinical research, and there have been few clinical trials but still research is underway to hope there is a chance that such findings will fill the gap between the naturopathic efficacy and modern precision medicine (Magne et al., 2023).

1.2 Importance of Commercialization in Advancing Naturopathic Therapies

Nano cardio-nutraceuticals have shown their laboratory applicability but it is the commercialization factor that significantly decides on uptake within clinical and consumer environments, especially within the context of naturopathic medical systems which put more stress on natural, non-invasive treatments. Based on a tradition of holistic treatments and predictive medicine, naturopathic treatments have long faced problems in standardization, evidence of efficacy, and advocacy to the market because of the inconsistent sourcing of natural compounds and adverse pharmacokinetic principles. Nanotechnology seals these holes based on delivery uniformity, yet unless industry focuses strategies are employed in commercialization, it includes regulatory permission, intellectual property ownership, scale-up manufacture and introduction into the market, such improvements are likely to be trapped and stagnate in the university cloisters. Commercialization has

many facets of importance. First, it can hasten evidence-based validation with funded clinical trials to allow the use of nutraceuticals such nano-encapsulated curcumin or resveratrol scale out of in vitro and animal models and to human use (Polak, Bravery, & Prescott, 2010).

One such regulation is the use of regulatory established pathways like te Generally Recognized as Safe (GRAS) status through nanoforms of natural products of the U.S. FDA, which could facilitate faster approval, which could build confidence among healthcare professionals and consumers. The creation of commercial possibilities in nanomedicine contributes to economic feasibility, whereas the global nanomedicine market will rise, estimated between USD 198.93 and USD 428.47 billion by the year 20125 and 2035 respectively at a CAGR of 8.0, as nanomedicine requires targeted CVD treatment options. Under this, nano cardio-nutraceuticals exploit the expanding nutraceutical market, of USD 400 billion across the world by providing high end products enjoying bio-availability at a superior formula. Commercialization, as an empowerment tool in naturopathic cardiovascular therapy, facilitates the incorporation into mainstream wellness ecologies, e.g. dietary supplements and functional foods. It enables alliances between biotech companies, herbs suppliers, and pharmaceutical companies as observed in emerging partnerships regarding nano-emulsion based formulations of omega-3 acids to lower the chances of hypertension. In addition, it deals with equity in access; producible at scale, the costs of these therapies are dropped to enable their use in low-resource environments where the burden of CVD is greatest. There are challenges such as intellectual property disputes, ethical sourcing of natural compounds, which must be overcome, yet performance models (such as liposomal vitamin C supplements) are a clear example of how commercialization can extend support to naturopathic effects, and displace dependence on synthetic medications which lead to sustainable health outcomes. Finally, commercialization not only maintains innovation by reinvesting revenue but also with various health agendas nationwide such as the focus on traditional medicine by WHO, nano cardio-nutraceuticals forms a pillar in the future of preventing CVDs (Wang et al., 2023).

1.3 Objective and Scope of the Chapter

The aim and scope of this chapter are presented. The goals of this chapter can be defined as the complete overview of the commercialization dynamics and market trends developing nano cardio-therapeutics and, specifically, as a subset of naturopathic innovations, nano cardio-nutraceuticals can be offered. The major aim is not only to explain how nanotechnology delivers therapeutic advantages to natural compounds in cardiovascular studies, but also to examine obstacles and opportunities towards commercializing such to commercially viable products. It is by compiling current literature, market data, and case studies that the chapter aims to give researchers, clinicians, and industry stakeholders strategies to fast track adoption, and to be able to fairly impact the world.

This scope includes:

(1) The survey of the main nano-formulation technologies and their cardio-specific applications

(2) The observation of the commercialization routes, including the world of the regulatory regulations (i.e., the FDA, EMA regulations of nanomedicine) and the funding system

(3) The existing and predicted commercial outlook, i.e., 10.86% CAGR of nanomedicine by 2033, with specific attention paid to the integration of nutraceuticals.

2. CURRENT MARKET LANDSCAPE: SIZE, GROWTH PROJECTIONS, AND KEY SEGMENTS

Nano-cardio therapeutics is a developing interface between nanotechnology and cardiovascular medicine, which is poised to relieve the growing global burden of cardiovascular disease. The World Health Organization states that cardiovascular diseases are the main cause of death in the world, as the diseases take the lives of more than 17.9 million people per year. Regardless of their efficacy, traditional therapeutics are often faced with the following challenges such as less-than-optimal bioavailability, non-specific target, and systemic toxicity. Nano-cardio therapy- Nano-particle drug delivery formulations, nano-formulated anticoagulants, and targeted stents represent precision interventions, which increase the efficacy and possibly patient outcomes (Elendu et al., 2025).

This section reviews the existing market volume, growth trends, and segmentation of the larger cardiovascular therapeutics industry, and specifically nano-based technologies. It also follows the development of nano nutritional as wellness supplements and the regional differences and outlines the

competitive ecosystem. Recent industry reports show that the global cardiovascular therapeutics market alone has a value of about USD 160 billion in 2025 and the nano-subsegments are expected to continue growing at an average rate of over 10 per cent each year due to regulatory incentives and technological and developmental investments.

2.1 Current Cardiovascular Therapeutics Market: Size, Segments, and Growth

The market value of cardiovascular therapeutics in the year 2025 is estimated at USD 160.39 b because it is an indicator of a good recovery of the shocks that the pandemic had caused and the continued need of new therapeutics. It is projected to grow by USD 188.663 billion in 2030 to achieve a compound annual growth rate of 3.3 percent. This trend is anchored by the trends in demographics whereby the number of people in the world who will be aged above 65 years is projected to reach 1.5 billion by 2050 and the growing cases of lifestyle related heart diseases, including hypertension and heart failure. The use of digital health technologies such as AI-driven monitoring systems can be seen as market resilience, as the latter can be integrated with therapeutic innovation (Fortune Business Insights, 2025).

Key segments delineate the market's structure:

- By disease indication: Hypertension takes the number (28.9% share) in 2024 with a value of about USD -46billion because it is prevalent across the demographic lines. Antihypertensive agents like the ACE inhibitors and ARBs remain in the lead with regard to therapeutic use but nano -formulations like lipid nanoparticles that target the renin-angiotensin system are emerging and are expected to dominate 5-7 per cent of this segment by 2030. With a 4.01⁻ CAGR, heart-failure therapeutics is a high-velocity market that is being driven by the introduction of finerenone and GLP-1 receptor agonists. Nanocarrier uses in this regard include polymeric nanoparticles that permit the gradual discharge of beta-blockers and this will result in a minimization of hospitalization rates by approximately 20 percent during clinical studies.
- By Drug Class: The biggest market is made up of anticoagulants and antiplatelets (35% of the market, USD56bn), with novel oral anticoagulants (NOACs) like apixaban taking up 40% of the sales. The 30% increase in bioavailability of nano-enhanced formulations e.g. PEGylated liposomes used in thrombolytic therapy and clot specificity in acute coronary syndromes are achieved respectively. They are antihypertensives, such as statins, with a dominance of 25 per cent market share and nano-lipid particles that are directed to atherosclerotic plaque, are growing at a 5.2 per cent CAGR, aimed at the market niche of PCSK9 inhibitors.
- By Distribution Channel: The hospital pharmacies control 53.45% (USD 85.7 billion) bolstered by procedural integrations like nano-coated stents during interventions. Telehealth services are driving the growth of online pharmacies, which have a 4.67% CAGR of growth, and nano-nutraceutical hybrids, such as ω - nano-emulsions, are growing their e-commerce penetration to 15 percent (Towards Healthcare, 2025).

The forecasts of growth highlight nano-integration as a multiplier: the aggregate market growth of 3.3 percent CAGR masks the 10-15 percent trend of nano-subsegments, say Mordor Intelligence. The number of cases of heart-failures in the United States alone is projected to rise to 8.5 million by 2030 due to which the demands of nano-targeted therapies that reduce the readmission expenses by 25 percent will increase. The opportunities remain high in the biosimilars and gene-editing hybrids, such as CRISPR-nano conjugates to treat familial hypercholesterolemia; however, the challenges exist in the form of high R&D expenditures (average USD 2.6bn/drug), and regulatory barriers (Technavio, 2025).

Table. 14.1. Cardiovascular Nanomedicine Market Segmentation (2025–2030)

Segment	2025 Market Size (USD Bn)	Share (%)	Projected CAGR (2025-2030)
Hypertension	46.3	28.9	3.2
Heart Failure	32.1	20.0	4.01
Anticoagulants	56.1	35.0	3.5
Hospital Pharmacies	85.7	53.45	3.1

This segmentation underscores nano-cardio's pivotal role in elevating efficacy, with early adopters reporting 15-20% improvements in patient adherence.

2.2 Evolution of Nano-Nutraceuticals in Healthcare and Wellness Sectors

The development of nano-nutraceuticals, which use nanotechnology to improve the body absorption of their active ingredients, has transformed these products from specialized dietary supplements into essential elements for cardiovascular disease prevention. The industry started in the early 2000s when basic vitamin nano-encapsulation began but it has now developed into a USD 636.31 billion market which will continue to grow until it reaches USD 1.234 trillion by 2034 with a 7.64% compound annual growth rate. The current growth pattern demonstrates a fundamental change in medical practice because nano-formulations now provide solutions for managing cardiovascular disease risk factors which include inflammation and oxidative stress (Magne et al., 2023).

The evolution traces three phases:

- The period from 2000 to 2015 marked the beginning of research to develop methods for improving solubility through nano-curcumin, which scientists used to test its anti-inflammatory properties on endothelial dysfunction. The first studies demonstrated that bioavailability increased twenty times, which led wellness brands to begin using nano-vitamins C and E as antioxidant products for heart protection.
- Expansion (2016-2022): Scientists developed functional foods through their research on probiotics which they successfully delivered using liposome-based nano-encapsulation techniques. The COVID-19 pandemic led to a faster adoption of nano-omega-3 products which helped support vascular health during periods of reduced physical activity.

- Maturation (2023-2025+): Personalization via AI-driven nano-delivery; e.g., gellan-based nanoemulgels co-encapsulating hydrophilic/hydrophobic nutraceuticals for sustained release. In January 2025, Indian researchers unveiled such systems, boosting absorption by 40% for cardio-nutraceuticals like resveratrol.

Medical treatments in healthcare receive extra advantages from nano-nutraceuticals because Nano-coQ10 aids patients who suffer from muscle weakness caused by statin drugs and "beauty-from-within" products which hold 6.4% market share will enter the market in 2025 because they create solutions for vascular aging. The market shows new patterns which combine adaptogens with ashwagandha nanoparticles to treat stress-induced hypertension while companies use plant-based nano-coatings to protect products from spoilage. The European Union's 2024 nano-labeling regulations create new standards which protect consumer safety through regulatory changes. The pediatric market will grow at an 8.22% compound annual growth rate until 2030 because of these upcoming safety regulations. The industry faces a major challenge from the expensive nature of nano-formulations which cost 20-30% more than traditional products according to WHO estimates that forecast a 10% reduction in CVD events through preventive solutions according to Durazzo et al. (2020).

2.3 Regional Market Analysis

Regional disparities in nano-cardio adoption reflect healthcare infrastructure, regulatory maturity, and CVD prevalence. North America leads with advanced R&D, while emerging markets lag but show explosive potential (Farjadian et al., 2019).

Table. 14.2. Regional Nanomedicine Market Outlook (2025–2030/2034)

Region	Market Size (2025, USD Bn)	Global Share (%)	Projected CAGR (2025-2030/34)	Key Drivers	Challenges
North America	105 (Cardio: 38.45)	39.9	8.01% (to 2034)	High CVD prevalence (e.g., 6.7M heart failure cases in U.S.), NIH funding (USD 1B+ annually), FDA approvals (e.g., Alnylam's RNAi therapeutic)	Reimbursement gaps, High R&D costs (USD 2.6B per drug)
Europe	66	25.0	11.7% (to 2030)	EMA regulatory support, High CVD burden (4.2M cases/year), Horizon Europe grants (EUR 1B by 2027)	Post-Brexit funding fragmentation, Regulatory complexity

Asia-Pacific	74.71 (Cardio devices focus)	28.3	10.5% (to 2030)	Aging population (Japan: 29% over 65), India's 26.7M CVD DALYs, China's nanoemulgel innovations	Regulatory harmonization lags, Infrastructure disparities
Emerging Economies (Middle East, Africa, Latin America)	26	10.0	12% (to 2030)	High unmet needs (e.g., 2.5M CVD deaths in Latin America), Brazil's nano-stent trials, UAE's USD 500M nano-hub	Limited healthcare infrastructure, Affordability barriers, Low nano-adoption

2.4 Competitive Landscape and Leading Market Players

The nano-cardio therapeutics market remains partially consolidated because its leading companies control 60 percent of the market through their research and development partnerships and their acquisition practices. The research project aims to create theranostics which integrate diagnostic tools and therapeutic treatments during the time when nanopharmaceuticals will grow at a 14.8 percent annual rate according to the DelveInsight 2024 report. Leading players: • Pfizer Inc. holds a 15% market share and currently dominates the market with its nano-lipid Vyndaqel product for amyloidosis which will generate 10 billion US dollars in revenue during 2025. The company implements mergers and acquisitions as its main business strategy which includes its planned acquisition of Seagen in 2024 to obtain ADC nanoparticle technology.

• Novartis AG holds a 12% market share because its Entresto nano-hybrids control the heart failure market which produces 6 billion US dollars in revenue. The 2025 Blackstone partnership will introduce Anthos as a CVD gene-editing solution. • Bayer AG holds a 10% market share through its Xarelto nano-formulations which provide anticoagulation treatment. The FDA will approve digital platforms in March 2025 to improve patient monitoring capabilities.

• Abbott Laboratories holds an 8% market share through its Bioabsorbable stents which have nano-coatings. The TCT 2024 event will present new technology developments which are expected to drive industry growth of 20%.

• Johnson & Johnson holds a 7% market share through Janssen's nano-thrombolytics. The 2025 Merck merger will bring together nanomaterial technology from both companies. Alnylam (RNAi therapeutics) and Regeneron (monoclonal nano-antibodies) emerge as disruptive forces through their biologic solutions which enable 40% pipeline development to reach Phase III trials.

The two organizations use partnerships for their strategic goals which include the Novartis-Verve collaboration dedicated to gene-editing research and their sustainability efforts. The high rivalry within Porter's Five Forces system receives a 7/10 score because of IP disputes while nutraceuticals maintain low entry barriers which drive industry progress. Market concentration will reach 70% by 2030 because leading companies will merge with each other. The nano-cardio therapeutics market will grow from 160 billion US dollars in 2025 to its future state which will create precise medical solutions that connect therapeutic methods with wellness practices for worldwide CVD prevention according to Lucintel's report.

3. COMMERCIALIZATION PATHWAYS FOR NANO CARDIO-NUTRACEUTICALS

The field of nano cardio-nutraceuticals creates a novel combination between nanotechnology and nutraceuticals and cardiovascular health management. The products use nanoscale delivery systems which include nanoparticles and liposomes and nanoemulsions to improve the bioavailability and targeted delivery and efficacy of bioactive compounds which include omega-3 fatty acids and polyphenols and antioxidants that work to prevent or reduce coronary artery disease (CVD) development. The study includes nano-encapsulated resveratrol which shows anti-inflammatory effects and curcumin-loaded nanoparticles which reduce plaque. The global CVD burden requires these technologies to be commercialized because CVDs will cause more than 23 million annual deaths by 2030. The research-to-market process requires companies to work through multiple obstacles which include regulatory requirements and intellectual property (IP) protection and funding acquisition and cross-sector collaborations. This section provides essential strategies through established models which create pathways from laboratory innovations to consumer products that serve a market projected to reach $61.5 billion for bioidentical and nano-enhanced health solutions by 2032 (Pillai et al., 2021).

3.1 From Laboratory to Market: Technology Transfer and Licensing

The path from laboratory research to commercially viable nano cardio-nutraceutical products begins when technology transfer processes move scientific innovations from educational institutions and research facilities to business organizations. The process typically requires research facilities and university laboratories and independent research institutions to select which nanoscale formulations should be patented to protect their work. The process of transferring technology successfully needs strong IP management through complete patent protection which starts with US Patent and Trademark Office and European Patent Office patent applications for new delivery systems according to (Rambaran & Schirhagl, 2022).

The system uses licensing agreements which enable inventors and institutions to transfer development rights for their products to companies which handle manufacturing and distribution. The adoption of nanotechnology will speed up through open licensing systems which permit public access to foundational patents while still generating royalty payments. The strategy enables organizations to lessen financial threats from research and development expenses which exceed 10 million dollars for nano-formulations because of the difficulties in making their particles maintain stability during solid-state operations. The United States FDA applies existing dietary supplement rules to nano-enabled nutraceuticals while requiring extra safety information about novel nanomaterials according to current regulations which need no new rules to control identified dangers. The European Medicines Agency (EMA) and Novel Foods Regulation in the EU demand comprehensive toxicological studies for nano-ingredients which need to evaluate both particle size and bioavailability enhancement (Morigi et al., 2012).

The transfer of nano-emulsion technologies for nutraceutical delivery to commercial partners by universities through their IP licensing agreements with health product companies demonstrates successful achievement. The research shows that global markets face two major challenges for IP enforcement while university tech transfer programs tend to favor developed countries over low- and middle-income nations. The market needs exclusive licensing agreements which permit high-margin products to use their patents and non-exclusive agreements which allow more general product use. The current phase requires scientists and legal experts and business developers to work together for evaluating market potential and conducting pilot projects and acquiring initial funding through National Institutes of Health grants and Horizon Europe programs (Hu et al. 2022) funding.

3.2 Startup Ecosystem and Spin-offs

The startup ecosystem forms a fundamental system which drives the process of turning nano cardio-nutraceuticals into marketable products while supporting rapid innovation through academic institutional spin-off ventures. Researchers establish spin-offs to turn their laboratory discoveries into commercial products which include polymeric nanoparticles designed to specifically deliver flavonoids into arterial tissues, which help decrease oxidative stress experienced by CVD patients. The organizations receive assistance from incubators and accelerators which include National Nanotechnology Initiative (NNI) programs in the United States that supply initial funding together with mentorship and access to common prototyping space. Worldwide, more than 100 active nanotechnology startups operate in the health and nutrition sector. The main companies in 2024 will develop quantum dots and carbon nanotubes which enhance nutraceutical stability to treat CVD through extended compound half-life. The ecosystems found in Silicon Valley Boston and Israel's nanotechnology cluster permit fast product development because they combine government funding with venture capital investment. The bureaucratic system in Israel created operational issues which forced businesses to change their direction which resulted in the development of nano-delivery systems for cardio-nutraceuticals.

The funding process needs to receive special attention because early-stage companies depend on life sciences venture capitalists to fund their operations. The 2025 global startup reports show that nanotechnology ecosystems have achieved a 13 percent increase in their development. The process of clinical validation presents major obstacles because nano cardio-nutraceuticals need to complete Phase I/II trials through testing that requires direct collaboration with contract research organizations for their bioavailability assessments. The success of RiboSense's biosensor diagnostic technology development shows how startup companies use their university patent assets to secure their first round of venture capital investment. Government-supported incubators in India assist nano-biotechnology startups through their research programs which combine traditional Indian herbs with modern nutraceuticals to create CVD prevention solutions. Startups need to

establish their manufacturing capabilities, follow all industry regulations, and develop their market entry tactics which include using e-commerce direct-to-consumer sales for their initial market presence (Subcommittee on Nanoscale Science, Engineering, and Technology, 2024).

3.3 Collaboration between Pharma, Nutraceutical, and Nanotech Industries

The development of nano cardio-nutraceuticals requires different industries to work together because pharmaceutical companies provide their knowledge of regulations while nutraceutical companies bring their expertise in markets and nanotechnology provides its engineering capabilities. Pfizer and AstraZeneca establish partnerships with nanotech companies to develop drug-nutraceutical hybrid products through nanoparticle formulation technologies. Researchers use nanotechnology to create products that improve the water solubility of omega-3s which then treat heart inflammation without producing the side effects that occur from pharmaceutical drugs (Tamboli et al., 2025).

The nutraceutical industry uses nanotechnology to create high-end products that include gold nanoparticles for antioxidant delivery which will change the $100 billion obesity and cardiometabolic market. The biotech and nanotech fields of India showcase their best practices through their evidence-based solutions which use both biotechnological and nanotechnological methods. Joint ventures solve problems associated with bioavailability because nano-encapsulation technology increases absorption rates between five and ten times which allows for decreased dosage requirements and cost savings. The business structure consists of co-development agreements where pharmaceutical companies supply clinical trial resources while nutraceutical companies develop product formulas and nanotechnology companies build carrier systems. More than 95 companies provide nanoparticle solutions while over 80 CDMOs help with contract manufacturing operations. The ethical aspects of nanomedicine require fair pricing because the cost of nanomedicines decreases when production increases. The upcoming development of artificial intelligence will enable people to work together for customized nano cardio-nutraceuticals which will drive innovation forward while their regulatory activities protect safety. These business alliances speed up product availability in the market which helps more people to access treatment that will result in savings of trillions for worldwide healthcare expenses through CVD research prevention (Vijayasimha, 2024).

4. REGULATORY AND POLICY FRAMEWORKS

Nanotechnology application in nutraceuticals and therapeutics is a radical change in the field of innovation in health products. It has superior bioavailability, specificity and superior efficacy in preventive and therapeutic applications. Nevertheless, this combination also involves regulatory issues as nanomaterials have specific characteristics that include variations of absorption, distribution, metabolism, excretion (ADME), and possible toxicity in the nanoscale. This section examines world regulatory bodies and standards, approval of nano-nutraceuticals, quality control and safety concerns and intellectual property (IP) rights in nano cardio-therapeutics. Based on the proven models such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) it highlights the necessity of a stable, science-oriented regulatory response to create a balance between innovation and the protection of the lives of the population. FDA, EMA, and WHO are regulatory bodies and standards across the globe. International health product regulatory frameworks which apply nanotechnology, such as nano-nutraceuticals, are cautious with case-by-case approaches to new threats of nanomaterials (Rodríguez-Gómez et al., 2025).

4.1 Global Regulatory Bodies and Standards (FDA, EMA, WHO)

The FDA operates as the main regulatory authority in the United States which controls all applications of nanotechnology through existing regulations that include the Federal Food Drug and Cosmetic Act (FD&C Act). The nano-nutraceuticals function as dietary supplements which require compliance with the Dietary Supplement Health and Education Act (DSHEA 1994). The substances are presented to consumers as food products instead of pharmaceutical treatments. The process requires compliance with Current Good Manufacturing Practices (cGMPs) which governs safety and labeling requirements while pre-market approval remains unnecessary. The 2014 FDA guidance document named Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology defines products which have been engineered to exist between 1 and 1,000 nanometers and display special characteristics. The product's specific characteristics require evaluation through safety and efficacy assessments. The 2017 guidance on Drug Products Containing Nanomaterials requires nanomedicines to assess their physical characteristics and chemical attributes through

size and surface charge testing and their toxicological assessment through immunotoxicity and biodistribution measurements. The FDA has approved over 50 nanotechnology products which include liposomes for drug delivery but it has warned about the dangers of nanoparticle aggregation and long-term exposure (Sindhwani & Chan 2021).

The European Medicines Agency (EMA) partners with the European Food Safety Authority (EFSA) to enforce nano-nutraceutical regulations which follow Regulation (EC) No 178/2002. The regulation requires risk evaluation for any new food products that include engineered nanomaterials which the Commission recognizes as materials containing at least 50% of their particles within the 1-100 nanometer range. The regulations of food supplements (2002/46/EC) under which nutraceuticals are processed require the notification rather than pre-authorization. EFSA analyses health claims using scientific evidence. The EMA guideline documents for nanomedicines require non-clinical data about biodistribution and immunogenicity according to the 2023 Reflection Paper on Surface Coatings to Parenteral Nanomedicines. The EMA report about medicinal products which use nanotechnology shows more than 100 approved products including liposomal formulations and it suggests using standardized methods to solve existing knowledge deficiencies about long-term safety evaluation. The FDA uses a voluntary reporting system while the EMA requires all nanomaterials to be registered under REACH for chemical safety (Kumari et al., 2023).

The 2017 WHO Guidelines on Protecting Workers in Potential Risks of Manufactured Nanomaterials provide comprehensive international standards which handle all aspects of occupational exposure during manufacturing and product usage. The WHO International Council for Harmonisation (ICH) establishes health product standards which require risk assessments for nanomaterials though it lacks direct regulatory authority. The organization supports standardized toxicity testing according to OECD guidelines and environmental impact assessment because additional data on long-term low-level exposure requires assessment. The WHO system operates according to ISO/TS 80004-1 which establishes terminology standards for international labelling and tracking systems. The organizations involved in this process emphasize the need for cooperation across multiple areas while current FDA-EMA parallel scientific advice activities have simplified international approval processes (United Nations Institute for Training and Research, 2011).

4.2 Approval Pathways for Nano-Nutraceuticals

The authorization routes of nano-nutraceuticals vary depending on the region because they have a hybrid nature between foods and therapeutics. Nano-nutraceuticals, in contrast to traditional drugs, do not necessarily undergo pre-market scrutiny, posing more risk to inconsistent safety regulation. The nano-nutraceuticals in the U.S. are regulated as dietary supplements in the DSHEA. They are not pre-approved by the FDA, but facilities must be registered and cGMP must be observed (21 CFR Part 111). The nanotechnology guidance issued by FDA is part of the New Dietary Ingredient (NDI) applications to new nanomaterials requiring 75 days to review safety data. In the case of therapeutic claims, products are required to use the drug pathway using either a New Drug Application (NDA) or Investigational New Drug (IND) application and have faster paths such as Fast Track of serious conditions. Since 2010 more than 25 nano-enabled supplements have made it to the market including nano-curcumin. But the labelling should not rely on unapproved claims to avoid fines. There exists a problem of showing that nanomaterials are stable and bioavailable without full clinical testing. The nano-enhanced nutraceuticals require pre-market authorization in the EMA/EFSA route (EU 2015/2283) (Puttasiddaiah et al., 2022).

The process implies a 9 months safety dossier which contains toxicological, genotoxicity and exposure data. Article 13 of EFSA evaluates health claims, and allows only substantiated claims to be approved, e.g. nano-vitamin D. MAA are centralized, and used in cases of hybrid products, and a PRIME scheme exists in case of innovative nano-delivery systems. Since 2020, the EMA approach centres on real-world evidence on the safety of nanomaterials. Decentralized processes will enable variations at national levels, which will lead to more than 15 nano-nutraceutical formulations approved by the EU by 2025. The WHO encourages such efforts by the global harmonization, which suggests OECD testing guideline of risk assessment regarding nanomaterials. New paths such as the FDA Regenerative Medicine Advanced Therapy (RMAT) label are used in nano-therapeutics to address unmet needs and reduce the time required to approve products to 6 months instead of 10-12. Despite these, standardization remains a challenge with continued calls to have a standardized nano-food category to be able to hasten the approvals and allow fairness in low resource regions (Jampilek et al., 2019).

4.3 Quality Control, Safety, and Standardization Issues

Nano-nutraceuticals have numerous problems with quality control (QC), safety, and standardization. These are the difficulties that are brought about by differences in nanomaterials, scalability of production and incomplete toxicity profiles. However, nanoparticles are different in their behavior regarding size, unlike bulk material. As an example, they are better able to penetrate through barriers because of the increased retention and permeability effect. This implies that they must be characterised carefully. The main issues of QC are variation in particle size, zeta potential, and morphology between batches. Such techniques as dynamic light scattering and transmission electron microscopy assist in this, according to the ISO/TS 80004 series. Good practice (cGMPs) with in-process controls are a requirement of the FDA and EMA to assure that nanomaterials are pure (greater than 99%) and stable according to the ICH Q1 guidelines. But the standardization is lagging. As an example, no universal means of quantifying the clumping of nanoparticles in biological media exist. Some of the safety considerations are cytotoxicity, oxidative stress, and immunotoxicity. It is observed by WHO that nanoparticles can cross barriers including the gut lining, this may lead to inflammation or bioaccumulation (Onyeaka et al., 2022).

In a 2023 review, the EFSA identified gaps in information on chronic exposure to oral nano-nutraceuticals. Approximately, 20 percent of the tested formulations generated unintended reactive oxygen species (ROS). Organizations such as OECD and ISO are leading efforts in standardization efforts including standards on how to identify hazards, such as OECD TG 471 on genotoxicity. The process of adjusting these to nano-forms, however, is not finished yet. At this moment, the interference of fluorescent nanoparticles is only considered in 30 percent of tests. The FDA and EMA post-market surveillance schemes (MedWatch and EudraVigilance) are significant, and underreporting is also an issue. Digital twins to improve QC and blockchain to provide traceability are possible solutions. They are also made to reduce recalls because the adulteration rates of nano-supplements are escalating by 15 percent since 2020. Finally, a combination of QC systems might serve to minimize risks to make sure that the nano-nutraceuticals will deliver the desired effects without causing any unforeseen side effects (Dini & Vergallo, 2021).

4.4 Intellectual Property Rights and Patent Trends in Nano Cardio-Therapeutics

Nano cardio-therapeutics has intellectual property rights (IPR) which safeguard the innovations. These are the delivery of statins and liposomal anti-hypertensives in nanoparticles. The protection invests in research and development in an expanding market that is set to reach $10 billion in 2030. New compositions, methods, and uses are patented. Nanotechnology is however, interdisciplinary which makes it difficult to patent it, with the common CPC classes being A61K (medicinal preparations), and B82Y (nanotechnology). According to the statistics of the U.S. Patent and Trademark Office (USPTO), the number of patent filings related to nano has increased by 35 percent each year since 2010. 15% of these filings are cardio-therapeutics. As an example, EP2858630A4 is about targeted iron oxide nanoparticles of ischemia. Trends show that there is increasing interest in hybrid systems and that 40% of patents between 2020 and 2025 involve lipid nanoparticles to deliver cardiovascular drugs, an increase in 25% in 2015. This is a reformed alteration occasioned by enhanced endothelial cell targeting. These activities are being spearheaded by major players such as Pfizer and leading academic centers such as MIT, which make 60 percent of the grants in the United States, China, and the European Union. The Unitary Patent system of the EMA makes the protection in the EU easier, however, there are difficulties (Antunes et al., 2013).

They consist of the necessity to share scalable synthesis procedures and does not divulge trade secrets and the generality of the definition of nanoscale. These general statements were found invalid and indefinite in 20 percent of the disputes. The WHO encourages open-access IP to ensure equity in health globally. But patent thickets have the potential to slow the penetration of generics into the market. A case in point is nano-stent coating legal fights have increased the market exclusivity by five years. Defensive publishing and cross-licensing groups are new approaches that aim to accelerate the cardio-nano innovation. These also involve siRNA loaded nanoparticles to treat atherosclerosis as in the case of patent WO2014047318A1. Since filings in BRICS countries are growing by a quarter every year, proper IPR will become essential in transforming cardio-nano breakthroughs into solutions accessible to all. Overall, it has been seen that regulations are changing to favour nano-innovation, although standardization and IPR harmonisation gaps still exist. Flexible evidence-based frameworks should be considered in future policies to get the most out of nanotechnology in nutraceutical and cardio-therapeutic approaches, with equitable global access (Siri et al., 2020).

5. MARKET DRIVERS AND OPPORTUNITIES

The cardiovascular disease (CVD) cardiac remains one of the most promising global markets that are expected to attain remarkable growth as attributable to the rising critical health issues and novel procedures. By 2025, CVD will still be the primary cause of mortality at a global level, with a figure of about 19 million deaths and over 500 million cases of prevalence, some nearly twice as many as in 1990. It is predicted that by 2050 there will be 91.2% increase in addition to a 23 percent lowering in the age-adjusted mortality rates mostly as a result of population aging and increment. This swell is a key indicator of why preventive measures must be used immediately, especially with respect to nanotechnology driven nutraceuticals, that improve the bioavailability of nutrients in preventing heart diseases. With valuation of higher than $400 billion around the world, the nutraceutical industry crosses with nanotechnology to provide a targeted solution with high venture capital. Prior factors and opportunities discussed in this section include preventative healthcare, consumer needs, technological advancements, and investment environments.

5.1 Rising Burden of Cardiovascular Diseases and Preventive Healthcare Demand

One of the primary market drivers is the increasing burden of CVDs with the demographic changes and risk factors as modifiable factors. CVDs also kill 19.6 million people in 2023 and have disability-adjusted life years (DALYs) of 393 million (39 more than in 1990 393 million DALYs), divided into 128 million caused by population growth and 139 million caused by aging. The major contributors are high systolic blood pressure, dietary risks, high cholesterol and increasing body mass index (BMI) indicating that there is a near doubling of crude mortality by 2050 in Asia relating to atherosclerotic condition such as ischemic heart disease (IHD) and stroke. Poorly funded healthcare in low- and middle-socio-demographic index (SDI) areas including Sub-Saharan Africa and Central Asia is known to worsen the problem, and more than 80 percent of deaths due to CVD happen in low-resource arrangements. This liability increases the pressure of preventive healthcare towards treatment that is reactive as opposed to proactive interventions.

Common preventive measures such as lifestyle changes and nutraceutical may prevent as many as half of events due to CVD, but the contemporary measures succeeded only in stabilizing the prevalence rate after age use. Nanotechnology-added nutraceuticals can be used to overcome this by enhancing the delivery of antioxidants such as omega-3s and polyphenols, which combat oxidative stress and inflammation, which are precursors of CVD. An example is nano-encapsulated curcumin, which has demonstrated the ability to decrease LDL cholesterol as well as inflammation of the endothelial in preclinical models. The preventive CVD division is also anticipated to be the largest, with an annual growth rate of 8.5% CAGR to 2030 due to the increasing awareness of these segments and their implementation on digital health systems. These are opportunities in region-based programs, e.g., in Asia-Pacific, CHO offers cure of the high-BMI population, nano-nutraceuticals mightceptively decrease the DALYs related to decreasing bioavailability and compliance (Martín Giménez et al., 2017).

5.2 Growing Consumer Preference for Natural and Naturopathic Interventions

Consumers are also showing tendencies towards going natural, naturopathic in an overall shift to wellness amid the skepticism of synthetic drugs. By 2025, 69% of Americans sought wellness objectives, and 35% are looking to sustainable, plant-based products and 28% are turning to hydrating plant-based foods with extra amounts of protein, such as heart. Complementary and alternative medicine (CAM) market comprising naturopathy and herbal therapies has reached its own talked-of value of $144.68 billion in 2023 (and projected to hit 694.22 billion in 2030), which has a CAGR of 25.3% thanks to the increasing popularity of non-invasive treatment. Worldwide, the sales of herbal medicine would better than 485 billion by 2028, with cardiovascular products such as cardiovascular drugs such as garlic, guggul and black cumin having their way through the market in management of cholesterol. This tendency is reinforced by the post-pandemic health consciousness in which 80% of women complain of menopausal symptoms associated with CVD fatalities, driving the sales of the so-called naturopathic supplements such as fenugreek and arjuna. Infusions and custom-made nutrition programs In Europe and Asia there are a boom in botanicals in infusions and personalized nutrition programs, with consumers becoming sensitive to sourcing that is eco-friendly- 35% believe in purpose-based brands. Nanotechnology fills this preference by stabilizing nature compounds like nano-emulsified omega-3s which enhances absorption (due to their stability) of compounds up to 4-5 fold, reducing dosage requirements and side effects. Such trends as microdosing NAD, hormone therapies through the prisms of naturopathy further combine with tradition. The customized products present good opportunities: 70% of Gen Z household

indicate interest in wellness retreats, meaning that they can be offered nano-enhanced gummies and soft-gels; the personalization offered by AI technology could open the potential of the functional food industry of 100 billion USD. Such obstacles as the harmonization of regulations are also present, yet in India, adaptive experiences such as Ayurvedic have proven scalable strategies to tackle CVDs (Hesari et al., 2021).

5.3 Advances in Nanotechnology-Enabled Nutrient Delivery Systems

Nanotechnology is transforming the entire way of delivering nutrients by providing specific bioavailable and accurate systems of managing CVD. Nanoformulations can improve solubility and targeted delivery of nutraceutical compounds by 2025, as a response to bioavangetic barriers such as curcumin (less than 1 capacity to increase absorption) and resveratrol. The most important are lipid nanoparticles of ometxa-3, which in clinical trials have increased the results of cardiovascular protection under 30-50 per cent, and mesoporous silica nanoparticles (MSNs) of honokiol, which prevent atherosclerotic intimal hyperplasia. Site-targeted Biomimetic nanoparticles imitate endothelial cells as agents of delivery in heart failure therapies minimizing the dose-toxicity exposure to off-target locations. Systems that respond to stimuli, e.g., pH-sensitive nanogels can be used to release cargo at inflamed plaques, whereas cardiac tissue regeneration can be achieved by using nanofibers and nanopatches (Han et al., 2025).

Nanoencapsulation of fruit-derived polyphenols in nutraceuticals enhances the antioxidant activity of these compounds against oxidative stress, which is a pathological feature of CVDs. Antiprolliferative coatings such as anti-expression of PLGA stents integrate the evidence of reduced restenosis shown by clinically tested stents (50 per cent less restenosis). The field also expands to theranostics, with the combination of imaging (e.g. gold nanoparticles to detect plaque) with therapeutic application, potentially reducing the cost of diagnostics by 25%. Whereas AI-neuromorphic nanobots and real-time monitoring can be used in the future to monitor the health of high-risk groups and deliver gene-editing agents using extracellular vesicles, it is important to note that this work continues, with representatives of both systems demonstrating faster delivery speeds and enhanced injury diagnostics. Such approvals as FDA nods of nano-omega-3 preparations provide access to the market, where the nanomedicine industry may reach a 12% CAGR and reach 350 billion dollars by 2030. New opportunities in CVD lie in hybrid systems which combine nutraceuticals with stem cell therapies which are projected to increase efficacy by 20-30 percent (Arshad et al., 2021).

5.4 Funding, Investment, and Venture Capital Trends

Nanotechnology-nutraceutical innovations are being energized by venture capital (VC), and by the year 2025, biotech funding is expected to have hit 80.1 billion in Q1, an increase of 28 percent a quarter-over-quarter. Startup Cardiovascular alone (e.g. Kardigan Series A cardiomyopathies) raised 300m in January 2025, and world VC reached 109billion in Q2, 45 percent in software-AI hybrids could be used in nano-delivery. The nutraceutical VC market is a young one, but cross-over opportunities abound: a 625M Sanofi Ventures investment in immunology, and rare CVDs, such as nano-platform10 nano-platforms Aviceda HaloStm inflammation. Funding of devices (decreased 62 percent since 2020) compares with increases in therapeutics with oncology and cardiology leading with 25 percent of VC directed at heart failure innovations (Prescott, 2010).

Investment funds such as Broadview Ventures and Racah Nanotechnology are focused on CVD tech, and in 2023, they have invested over 8.8 billion in medical equipment. The opportunities in Asia can be marked by the fact that the figure in June 2025 will be 25.73billion. Examples of investments made would be early-stage nano-nutraceuticals to prevent CVD, returns of 15-20% are expected with 694 billion CAM growth. High interest rates and similar challenges still exist, and the upticks to M&A (17 takeovers in 2024) provide exits. To close the cost gulf of CVD estimated at 400 billion annually policymakers ought to incentivize, as was done in the AYUSH Ministry in India, through grants. To sum up, common denominators among these drivers would bring a $500 billion opportunity in nano-enabled CVD nutraceuticals by 2030, requiring a willingness to collaborate in the research process and equal access to help reduce the global burden (Singh et al., 2022).

6. MARKET CHALLENGES & BARRIERS

The development of nano cardio-therapeutics as a commercial enterprise has many multifaceted obstacles complexing the mass use of nano cardio-therapeutics. These difficulties cut across the technical, financial, societal, and regulatory spectrums, which tend to accelerate the disconnect between the successful

preclinical achievements and the product that is marketable. In cardiovascular uses - where prompt treatment is paramount such as in atherosclerosis and heart failure- these obstacles do not only raise the costs but also the time that patients obtain potentially lifesaving treatment. To deal with them, there should be a concerted effort by regulators, industry, and academia to harmonize operations and develop trust. This part also discusses the main barriers, which are based on the recent observations in emphasizing their impact in the development of the field.

6.1 Production Expansion and Economic Concerns.

Nanoparticle production on a larger scale to produce cardio-therapeutics is still a daunting technical and costly challenge mostly because of the complexity involved in nanomaterials production and maintenance of high-quality standards. Historical lab scale approaches (wet chemistry or microfluidics) are good at making small batches of particles that are uniform in size and have identical uniformity--important when targeted at cardiac tissues, any deviations of which would result in off-target effects or decrease therapeutic efficacy of plaque removal. The shift to industrial production, however, brings a changing variable of aspects such as dynamics of mixing, regulation of temperature and solvent evaporation which in most cases lead to inconsistent physicochemical properties making reproducibility difficult (Augusto et al., 2020).

One of them is the multi-step fabrication involved in most nano cardio-formulations (liposomal and polymeric nanoparticles), which are travelling with anti-inflammatory agents to atherosclerosis. They need successive processes such as emulsification, purification and lyophilization and increase the chances of aggregation of degradation during amplification. As an example, conversion of grams to kilograms may change shear forces in reactors with the result of polydispersity indices that are larger than acceptable (for clinical practice typically less than 0.2) and requires expensive redesign or extra validation. The dependence on special equipment, including high-pressure homogenizers, is another factor that worsens the industrial applicability of this method since they are costly in addition to consuming a lot of energy, a factor that leads to the environmental issue in sustainable manufacturing (Milewska et al., 2021).

These technical ills are compounded by cost barriers. Nanomedicines are resources that are themselves more expensive to manufacture than traditional drugs and the raw material such as phospholipids or gold nanoparticles has price added since they are limited and demand purity. Some estimates indicate that therapies based on nanoparticles may cost 5-10 times more per dose than small-molecule counterparts, which are due to the requirement of cleanroom technologies and sophisticated analytical tools (e.g. dynamic light scattering to size characterize nanoparticles). In cardio-specific studies, where functionalities have to survive physiological demands such as shear forces during blood flow, further increase of costs are associated with further coatings or functionality additions. Today, AAV-based nano-gene therapies of the heart fail have shown promise, yet it will be costly to scale to $500 million per product which is prohibitive to smaller biotech unless partnering with big-pharma, leading one author to note in 2025. Such problems extend the time-to-market as well as requirement to cost-effectiveness, with estimates showing that the absence of innovations such as automated microreactors can keep nano cardio-products a niche product, available only in the wealthier markets. Some of the mitigation strategies include embracing continuous flow manufacturing to increase yield consistency and minimum waste, and joint access of GMP-compliant facilities, through public-private consortia. Finally, it is crucial to sort out scale-up bottlenecks that will help college-level access to such advanced therapy (Nam & Luong, 2019).

6.2 R&D Expenses and Long Development Lead Times

The current state of the nano cardio-therapeutic R&D is marked by the excessive spending of money and extended development period indicating the infantile stage of the field and the necessity to coordinate nanotechnology and cardiovascular biology. The worldwide expenditure on nanomedicine research and development has been on a rising trend and is expected to reach some $10-15 billion on average by 2025, and the cardiovascular applications are expected to have a substantial portion of this sum since CVDs impose an economic cost of about 1 trillion a year. Nonetheless, the cost associated with making a single project can easily run up in the billions of dollars whereas the average price of a traditional small-molecule drug is generally between $500 and $800 million. This is because the multidisciplinary skills (including materials science, pharmacology, and cardiology) are required due to the necessity of exposure to iterative prototyping to maximize nanoparticle biodistribution in living cardiac ecosystems (Sertkaya et al., 2024).

Financial pressure is worsened by development cycle which usually takes 10-15 years to bench-to-bedside, before traditional therapies can take 8-10 years. The preclinical phases in themselves may take up to 3-5 years of time; during which, it includes a series of in vitro/in vivo models to confirm targeting mechanisms, including in atherosclerotic plaque, EPR (enhanced permeability and retention). Regulatory scrutiny provides additional levels: the required data on pharmacokinetics, immunogenicity and long-term biocompatibility when using nanomaterials are those that are nanomaterial specific, and sometimes those non-clinical studies are mandatory in new vectors such as lipid nanoparticles. Large cohort studies (n>500) are required in clinical trials (especially Phase II/III indications of heart failure) to show the superiority over other therapies, especially beta-blockers, further driving up the cost against high attrition rates, which are over 90 percent of nano cardio-candidates do not pass clinical trials (Lee & Choi, 2015). These cycles are extended in case of disease heterogeneity in cardiovascular nanomedicine; to design nanoparticles tailored to different disease issues (e.g. ischemic and hypertensive heart diseases) adaptive designs are needed that slow down milestones. A 2024 review observes that though such innovations as siRNA-loaded nanoparticles to manage cholesterol have preclinical promise, only 5-7 come to the point of approval, an important factor to being in the valley of death between discovery and commercialization. Despite rising venture money (e.g. 2.5 billion in 2024 oncology nano-biotechs) there is a switch over oncology to cardio meaning vacant capital in case has a long schedule. In the end, these obstacles will threaten to suppress innovation unless expediency channels, including FDA Breakthrough Therapy Designation, are applied more easily. Possible approaches such as AI-based predictive toxicity screening would allow cutting the cycles by 1-2 years to create a more viable pipeline (Simoens & Huys, 2021).

6.3 Market Education, awareness, and acceptance of consumers.

Nano cardio-therapeutics is not a widely accepted among the community as technology is and there is a significant gap in the knowledge about the topic subject of nano cardio-therapeutics, is thus it is factual that it is one of the biggest hurdles in terms of entry and entry of the market. Only 20-30 percent of the consumers in the developed economies can be said to be fully informed of nanotechnology in the medical industry, and this is half of half in other emerging markets like Jordan where nano education is primitive. Such a gap of knowledge induces scepticism especially in cases where one tries to employ the nanoparticles in an invasive mode like in arrhythmia treatment where the issue of nano-toxicity or lack of understanding the long-term effects takes priority over benefits as less dosing and fewer side effects relative to oral statins (Kim et al., 2014).

Even its adoption by healthcare providers as one of the major influencers is not evenly spread, a 2023 study found that it is oncologists who adopt nanomedicines, cardiologists note that they are not taught to do so, only 15% of cardiologists note that they are confident in prescribing them, and practice restrained prescribing behaviour. The problem of misinformation aggravates the level of patient acceptance as it is strengthened by social media and uses a tactic to treat nanoparticles as microplastics or the dystopian threat. The nano-products launched new must solve the issue of inertia in the cardio case where the current therapeutic treatments, including ACE inhibitors, already have a long presence: regenerative nano-patches to repair myocardium is not doing well, despite the safety of the Phase I results (Desai et al., 2025).

Education programs have not yet become mature, but extremely important. Educational programs like Nano Safety Cluster of EU are aimed at sharing the evidence but with low coverage of less than 5 percent of CVD patients being exposed to campaigns. Market research predicts this adoption can be raised by 20-25 percent in 2030 with greater awareness, which currently is not achieved because of the flaws of the current programs like patient leaflets or webinars that need to be culture-specific, e.g. lower awareness of holistic medicine in Asia-Pacific. This gap needs to be bridged with multi-stakeholder strategies: pharma-sponsored-CME to physician application, to helping to overcome the knowledge barrier about pharma-nanoparticle medicine delivery open labelling to bring about informed adoption and uptake. Online communication, e.g., nano-mechanism VR simulator, can be improved faster to foster trust, and adversity can serve as an opportunity to increase the market share (Giles et al., 2015).

The competitiveness against traditional drugs/supplements as well as the morality of the matter also comes in.

6.4 Ethical Concerns and Competition with Conventional Drugs/Supplements

The Nano cardio-therapeutics encounters ethical dilemma as a grey area between regulatory uncertainty and strong point competition with known conventional substitutes, but associated with equity, safety, and societal value as well. First is the problem of risk assessments: on the one hand nanoparticles contribute to the degree of accuracy (e.g. local release of vasodilators), on the other hand uncertainty about bioaccumulation in heart tissues or the transmission of these particles to ganglionic cells pose the problem of improvement versus lifestyle improvements on the subject. Their vulnerability may also be used to exploit the elderly CVD patients and other at-risk groups in trials since; therefore, attempts must be made to institute a sound informed consent process that can afford them a chance to understand the dynamics of the nanocycles but without overwhelming the non-experts (Ebbesen & Jensen, 2006).

Regulatory elements of ethics compound the issue even more; the FDA nanomaterial standards, despite constant amendments, are lagging innovative development, introducing an off-label use, which renders safety grey. The nano versions will also need to prove not only efficacy but also ethical superiority, like lower ecological selection ability due to ability to dose low amounts, but also high prices ($10,000+/treatment vs. $50/month generics) exacerbates inequalities of access which would contribute to health inequities. New grey lines of nutraceutical nano-formulations, supplements, and nanoparticles combination to increase bioavailability: in 2020, a report noted that 25% of the products worldwide announced itself to be nutraceutical bioavailable and another report introduced the phrase grey area because it is alone with suspicions and marketing failures to roll out untested assertion.

Larger nano ethics as envisaged in the AMA discussions introduce cautionary measures, such as, long-term surveillance on nano-agents instead of its correction, and open regulation to exclude abuse, such as weaponized nano-agents. Competition will only intensify as big pharma will transition to become hybrids, but until there are some kind of global standards that will guarantee harmonization, there will be ethical silos. These directions can be taken out through interdisciplinary ethics boards, shared costs, and evidence at work to prove the value of nano cardio-therapeutics at the cost of the low-cost staples in life. As ethical audits are introduced as part of the development pipelines, the sphere will be able to address the competition towards sustainable and fair innovation.

7. EMERGING TRENDS AND FUTURE DIRECTIONS

7.1 Integration of Artificial Intelligence, IoT, and Digital Health Platforms

The backing of nanotherapeutics and personalized nutrition will be AI, edge computing and IoT (wearables, ingestible, smart packaging) that will make it functional at scale. Machine learning algorithms trained on multimodal data (genetics, continuous glucose, activity, adherence to medication) will be able to predict a patient in need of an intervention and then a device that can deliver the intervention or a clinician can be prompted. Federated learning models and digital twins will allow personalisation of the models as well as ensuring privacy of their data. In the case of nanomedicine, AI may be used to enhance material discovery (prediction of nanoparticle composition and toxicity to specific materials), reduce manufacturing parameters, and enhance quality control through real-time sensor feedback. Closely, IoT-based drug delivery systems, either implantable or wearable, with nano systems enable closed-loop delivery wherein the dosage is altered in real time and enhances efficacy and safety. The problems are still (data interoperability, cybersecurity, validation pathways) and yet hybridization of nanotechnology with AI/IoT will offer dramatic changes in accuracy, compliance, and results.

7.2 Green Nanotechnology and Sustainability of Scalable Productions

With the transition of nanomaterials out of the labs and into industry, environmental impact and resource use is emerging as an imperative design constraint. The use of green nanotechnology- bio based synthesis (plant and microbial extracts), solvent free, low temperature-fabrication and recyclable nanocomposites, minimizes the risk of hazardous byproducts and energy usage requirements in addition to enabling the regulatory acceptance and community confidence. The concept of life-cycle thinking is infiltrating a formulation design: designing biodegradable delivered by carriers, reduced consumption of heavy metals, closed-loop production (closure of waste, recycling of catalysts) are becoming more familiar in industry guidelines. These strategies do not only reduce the environmental risk but also streamline the regulatory processing and approval of large-scale production. However, scaling green processes without

reducing reproducibility, batch consistency or cost will be a technical and economic challenge that will characterize competition in commercialization (Tamboli et al., 2025).

7.3 Forecasting Market Growth and Future Demand (2025–2040 Projections)

The field is estimated differently in the market due to these variations in definitions (broad nanotechnology, nanomedicine, specific products classes). Accredited recent studies estimate the nanomedicine market at the high hundreds of billions (IMARC estimated]. The estimate of the 2024 USD 294.0 billion of the nanotechnology market and more expansive market estimates of nanotechnology in 2025 (by methodology) by Mordor, Grand View, Precedence report with different baselines). Considering such distribution, scenario plan is most educational in 2025-2040 planning.



Fig. 14.1. Nanotechnology Market Size Forecast by CAGR Scenario (2024–2040)

Interpretation and caveats; such scenarios (USD 1.35-2.75 trillion by 2040 of nanomedicine under our assumptions) the upside is huge if the regulatory routes, mRNA /nanoparticle platform hits, and personalized medicine collide. On the other hand, a reduction in clinical translation velocity, supply-chain bottlenecks or regulatory/safety delays would overload the results toward the right. It should be noted that more inclusive other analyses of nanotechnology (such as materials, electronics, energy) use other baselines and higher short term CAGRs; hence, pick the definition of the market that best fits your strategic interest when utilizing such forecasts.

Strategic implications (2025-2040):

1. The investments companies need to make now are modular and scalable manufacturing and digital platforms to capture the growth at the earliest stage.
2. The collaborations will be cross-sector (nutrition, Medtech, AI, regulatory consultancies) and decrease the time-to-market of combined diagnostics/therapeutics.
3. Green synthesis and thorough environmental risk assessment will also be competitive advantages of sustainability and transparent safety data- investing in this will reduce the commercial friction.
4. To create and ensure investments worthwhile to nanotherapeutics aided by AI and IoT interconnectedness, policymakers and standard agencies must swiftly provide clear direction (Vijayasimha, 2024).

8. CASE STUDIES AND INDUSTRY INSIGHTS

The above sections have presented the market environment, commercialization strategies, regulations, and future projections of the Nano cardio-nutraceutical market in a systematic manner. This part seeks to bring to reality those theoretical discussions. It is possible to study the interaction among these forces and how they influence the direction of the industry by analysing case examples of commercial successes, market failures, and strategic alliances. The presented insights can be used to demonstrate the practical execution of the concepts discussed and can be of instrumental value in lessons to researchers, clinicians, and industry stakeholders.

8.1 Success Stories of Commercial Nano Cardio-Nutraceutical Products

8.1.1 Case Study: "CardioSorb-QL™" by PhytoNetic Solutions Inc.

Introduction: Another remarkable success history in the Nano cardio-nutraceutical industry is the CardioSorb-QL™, a liposomal Coenzyme Q10 (CoQ10) nutritional supplement, released by PhytoNetic Solutions. It was promoted as an excellent bioavailable product that is preferred to combat cardiovascular countermeasures of mitochondrial systems of the heart cells in direct response to increasing consumer preference for preventive cardiovascular healthcare.

The Case: Introduced in 2022, CardioSorb-QL is already able to establish itself as a winner in a saturated CoQ10 market. Two main pillars were the basis of its success. First, the organization placed its bet on a strong clinical trial showing much higher plasma CoQ10 concentrations than those of traditional crystalline CoQ10 supplements. Second, their marketing approach entailed informing the consumers as well as the healthcare practitioners regarding the advantages of the Nano-enabled nutrient delivery system. In only two years after launch, the product has managed to dominate approximately 15% of the superior CoQ 10 sector in North America.

Analysis: The achievements of CardioSorb-QL are a clear testimony of how technological advancement technology can play a potent market driver. Having actual, proven benefits (increased bioavailability), PhytoNetic Solutions warranted paying a higher price and developed a good brand loyalty. The case indicates that clinical validation and market education a significant factor in preventing consumer iconoclasm and succeeding commercially (Grand View Research, 2024).

8.2 Failures, Market Withdrawals, and Lessons Learned

8.2.1 Case Study: The Market Withdrawal of "Nano-CellaVex"

Introduction: Contrary to the successes, there is a warning story with the short-lived market of Nano-CellaVex, a purified fish oil Nano-emulsion, high in EPA/DHA. It was an innovative-looking product being developed by a fledgling company, NutriSphere Technologies, and was geared to provide, from the proposed innovative product, a flavour-masked, highly ferrous capsule form of fish oil instead of the traditional variety.

The Case: In 2023, Nano-CellaVex was launched, heavily venture-capital-financed. But in six months, the inconsistency of the product started to emerge. Customers noted differences in taste and texture, and independent laboratory evaluations showed high batch-to-batch fluctuations in senescence and size of the nanoparticle. This inconsistency caused a security issue that prompted the FDA investigation. Facing regulatory pressure and negative publicity, NutriSphere Technologies withdrew the product from the market voluntarily in early 2024.

Analysis: The failure of Nano-CellaVex underlines one of the most prominent obstacles in this field, the difficulty of scaling up manufacturing and quality regulation. Although the concept of the product was very good, the company could not commercialize a test at a laboratory level into a feasible, solid, and effective product. This incident is a sobering experience that innovation in nanotechnology has to be followed by equally strict measures in matters of quality assurance and standardized manufacturing procedures. It emboldens the necessity of well-defined regulatory routes of Nano-nutraceuticals so that their safety and effectiveness can be guaranteed once it is added to the market. Even part of the cost such as the financial losses made, would also show the protracted and expensive development phases that even well-financed start-ups struggle to overcome.

8.3 Academia–Industry Partnerships Driving Innovation

8.3.1 Case Study: The National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali)–Sun Pharmaceutical Industries Ltd. (one of India's largest pharmaceutical companies).

Introduction: One of the best examples of synergistic partnership that leads to innovation is the current cooperation between the nanotechnology research centre, The National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), and Sun Pharmaceutical Industries Ltd., one of the leading nutraceutical companies. This collaboration was established to overcome the delivery difficulties of pterostilbene, which is a potent, however insoluble, antioxidant that has high cardiovascular properties.

The Case: The partnership capitalizes on the strengths of both partners. The lab of the university came up with and patented a new solid lipid delivery system known as SLN, which proved effective in preclinical models. Nevertheless, they did not have the capability to conduct clinical trials and large-scale production. In

its turn, Canada-based CardiaHealth Pharma had licensed this technology to the university. This company is financing the human clinical trials and is leveraging on its experience in manufacturing and distribution to commercially release the product. This type of partnership is an archetypal one between the pharma, nutraceutical, and nanotech industries.

Analysis: This association can be taken as a perfect example of the transfer of academic research into commercial products with success. It is a leaner process to the lab-to-market process and ultimately de-risks the process of innovation without making either party accountable. In the case of the university, it offers them research funding together with a path to discoveries that can make a real-life difference. In the case of CardiaHealth Pharma, it will enable access to advanced technology with no huge initial expenditure on R&D. The model is vital in developing subsequent innovation and maintaining a healthy pipeline of upcoming generation Nano cardio-nutraceuticals (U.S. Food and Drug Administration, 2023).

CONCLUSION

The commercialization of nano cardio-therapeutics creates a fundamental medical revolution which establishes new cardiovascular treatment methods by integrating nanotechnology with nutraceutical and naturopathic methods to treat cardiovascular diseases that affect over 500 million individuals every year. The global nanomedicine market which currently values between USD 265 billion and USD 294 billion will reach a market value between USD 632 billion and USD 779 billion by 2034 after experiencing an annual growth rate between 10 percent and 12 percent. The industry expansion occurs because of advancements in nano-based drug delivery systems along with diagnostic tools and treatment methods while people increasingly demand tailored solutions that prevent diseases. The North American market leads the industry through its advanced research capabilities and regulatory systems while the Asia-Pacific market experiences fast development because of rising CVD rates and new treatment methods. The potential of nanotechnology to decrease oxidative damage and enhance cardiovascular health results through the use of nano-nutraceuticals which include curcumin and resveratrol and their various formulations. The process of bringing this product to market faces several major obstacles which include difficulties with biocompatibility and high costs of production and the need to comply with complicated regulations and ethical standards established by the FDA and EMA. The existing obstacles need solutions that require cooperation among academic institutions industrial companies and public-private partnerships which include major pharmaceutical firms like Bristol-Myers Squibb and Novartis and Pfizer. The future of development focuses on creating intelligent nano-systems which work together with artificial intelligence to achieve precise drug delivery and continuous health monitoring of diseases. The policymakers need to create policies which guarantee people can access resources while maintaining their safety and protecting environmental resources. The combination of ongoing innovation together with ethical governance will enable nano cardio-therapeutics to transform cardiovascular treatment through its integration of exact medical technologies and complete patient-focused healthcare methods which will transform cardiovascular treatment.

Acknowledgement

The authors would like to express their sincere gratitude to Deep Science Publishers for providing the opportunity to contribute to this work. Their continuous support, guidance, and commitment to academic excellence are highly appreciated. The authors also acknowledge all contributors whose efforts and cooperation made this work possible.

Authors' Contributions

All authors contributed equally to the conception, design, writing, and finalization of this work. Each author was actively involved in literature review, data interpretation, manuscript preparation, and critical revision. **Akansha Bisht** specifically contributed to drafting, grammatical modification, and overall quality improvement of the manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.

REFERENCES

1. Antunes, A., Fierro, I., Guerrante, R., Mendes, F., & de M Alencar, M. S. (2013). Trends in nanopharmaceutical patents. *International Journal of Molecular Sciences, 14*(4), 7016–7031. https://doi.org/10.3390/ijms14047016
2. Arshad, R., Gulshad, L., Haq, I. U., Farooq, M. A., Al-Farga, A., Siddique, R., Manzoor, M. F., & Karrar, E. (2021). Nanotechnology: A novel tool to enhance the bioavailability of micronutrients. *Food Science & Nutrition, 9*(6), 3354–3361. https://doi.org/10.1002/fsn3.2311
3. Augusto, P. A., Castelo-Grande, T., Vargas, D., Pascual, A., Hernández, L., Estevez, A. M., & Barbosa, D. (2020). Upscale design, process development, and economic analysis of industrial plants for nanomagnetic particle production for environmental and biomedical use. *Materials (Basel, Switzerland), 13*(11), Article 2477. https://doi.org/10.3390/ma13112477
4. DelveInsight. (2024). *Nanomedicine market size, target population, competitive landscape & market forecast – 2034*. DelveInsight Business Research LLP.
5. Dini, L., & Vergallo, C. (2021). Nanonutraceuticals delivery. *Nanomaterials (Basel, Switzerland), 11*(8), Article 2031. https://doi.org/10.3390/nano11082031
6. Teli S, Shah TM. Design solid lipid nanoparticle solid lipid nanoparticle (SLNs) of dapagliflozin for enhanced oral bioavailability and controlled release in type 2 diabetes. African Journal of Biological Sciences. 2022;4(1):287-306.
7. Elendu, C., Amaechi, D. C., Elendu, T. C., & Jingwa, K. A. (2025). Nanotechnology in cardiovascular medicine: A review of advancements and applications. *Medicine, 104*(3), e37012.
8. Vasanth S, Mishra R, Sahoo S, Parveen S, Khan Z, Mumtaz, Ruqaiya, Pal R. Advancing Mitochondrial Health in Huntington Disease (HD): Small Molecule Therapies and Neurodegeneration. Current aging science. 2025.
9. Fortune Business Insights. (2025). *Nanomedicine market size, share & COVID-19 impact analysis, by type (nanoparticles, nanoshells, nanotubes, nanodevices, and others), by nanoparticle type (gold nanoparticles, silver nanoparticles, iron oxide nanoparticles, alumina nanoparticles, gadolinium nanoparticles, and others), by application (therapeutics, in-vitro diagnostics, drug delivery, in-vivo imaging, and others), by end user (hospitals, diagnostic centers, research institutes, and others), and regional forecast, 2023-2030*. https://www.fortunebusinessinsights.com/nanomedicine-market-102323
10. Koli M, Shah TM, Dutta P, Patel N, Patel AK, Ghosh B, Singh A, Pal R. Non-Ionic Surfactants (NIOs) in Niosome Drug Delivery: In-Depth Review of Clinical Trials, Patents in Tuberculosis (TB) and Oncology. Current Nanomedicine. 2025. doi:10.2174/0124681873413153251014082026
11. Han, K., Yang, H., Fan, D., & Deng, J. (2025). Advances in nanotechnology research in food production, nutrition, and health. *Nutrients, 17*(15), Article 2443. https://doi.org/10.3390/nu17152443
12. Hesari, M., Mohammadi, P., Khademi, F., Shackebaei, D., Momtaz, S., Moasefi, N., Farzaei, M. H., & Abdollahi, M. (2021). Current advances in the use of nanophytomedicine therapies for human cardiovascular diseases. *International Journal of Nanomedicine, 16*, 3293–3315. https://doi.org/10.2147/IJN.S295508
13. Hu, Q., Fang, Z., Ge, J., & Li, H. (2022). Nanotechnology for cardiovascular diseases. *Innovation (Cambridge (Mass.)), 3*(2), Article 100214. https://doi.org/10.1016/j.xinn.2022.100214
14. Jampilek, J., Kos, J., & Kralova, K. (2019). Potential of nanomaterial applications in dietary supplements and foods for special medical purposes. *Nanomaterials (Basel, Switzerland), 9*(2), Article 296. https://doi.org/10.3390/nano9020296
15. Kumari, R., Suman, K., Karmakar, S., Mishra, V., Lakra, S. G., Saurav, G. K., & Mahto, B. K. (2023). Regulation and safety measures for nanotechnology-based agri-products. *Frontiers in Genome Editing, 5*, Article 1200987. https://doi.org/10.3389/fgeed.2023.1200987
16. Lee, M., & Choi, M. (2015). Analysis on time-lag effect of research and development investment in the pharmaceutical industry in Korea. *Osong Public Health and Research Perspectives, 6*(4), 241–248. https://doi.org/10.1016/j.phrp.2015.07.001
17. Shah, Tapaskumar. (2020). Advancing Formulation Science in Diabetes and Migraine: From Conventional Therapies to Precision Drug Delivery. Journal of Cardiovascular Disease Research. 11. 358-372
18. Gupta U, Kosey S, Pal R. Advancements in nanotechnology-based targeted drug delivery systems for glioblastoma chemotherapy: A comprehensive review. Journal of Drug Delivery Science and Technology. 2025 Sep 1;111:107181.
19. Martín Giménez, V. M., Kassuha, D. E., & Manucha, W. (2017). Nanomedicine applied to cardiovascular diseases: Latest developments. *Therapeutic Advances in Cardiovascular Disease, 11*(4), 133–142. https://doi.org/10.1177/1753944717692293
20. Milewska, S., Niemirowicz-Laskowska, K., Siemiaszko, G., Nowicki, P., Wilczewska, A. Z., & Car, H. (2021). Current trends and challenges in pharmacoeconomic aspects of nanocarriers as drug delivery systems for cancer treatment. *International Journal of Nanomedicine, 16*, 6593–6644. https://doi.org/10.2147/IJN.S323831
21. Morigi, V., Tocchio, A., Bellavite Pellegrini, C., Sakamoto, J. H., Arnone, M., & Tasciotti, E. (2012). Nanotechnology in medicine: From inception to market domination. *Journal of Drug Delivery, 2012*, Article 389485. https://doi.org/10.1155/2012/389485
22. Mishra R, Pal R, Khan Z, Sahoo S, Chawra HS, Kumar D. Solid lipid nanoparticles (SLNPs): a state-of-the-art formulation strategy and their applications against tuberculosis (TB) and analgesic effects. Nanoscience & Nanotechnology-Asia. 2025 Jun;15(3):E22106812379362.

23. Omidian, H., Dey, P., & Dey, S. (2023). Nanotechnology in drug delivery: Past, present, and future. *Pharmaceutics, 15*(2), Article 382.

24. Onyeaka, H., Passaretti, P., Miri, T., & Al-Sharify, Z. T. (2022). The safety of nanomaterials in food production and packaging. *Current Research in Food Science, 5*, 763–774. https://doi.org/10.1016/j.crfs.2022.04.005

25. Pillai, S. C., Borah, A., Jacob, E. M., & Kumar, D. S. (2021). Nanotechnological approach to delivering nutraceuticals as promising drug candidates for the treatment of atherosclerosis. *Drug Delivery, 28*(1), 550–568. https://doi.org/10.1080/10717544.2021.1892241

26. Pachani, Raj & Shah, Tapaskumar & Soni, Dhruv. (2021). Advances In Peptide-And Antibody-Targeted Nanocarriers For Cancer Therapy And Imaging. 28. 392-419. 10.53555/3sadmc24.

27. Prescott, C. (2010). Regenerative nanomedicines: An emerging investment prospective? *Journal of the Royal Society, Interface, 7*(Suppl 6), S783–S787. https://doi.org/10.1098/rsif.2010.0351.focus

28. Pal R, Pandey P, Chawra HS, Singh RP. Niosomal as potential vesicular drug nano-carriers for the treatment of tuberculosis (TB). Nanoscience & Nanotechnology-Asia. 2025 Feb;15(1):E22106812323829.

29. Puttasiddaiah, R., Lakshminarayana, R., Somashekar, N. L., Gupta, V. K., Inbaraj, B. S., Usmani, Z., Raghavendra, V. B., Sridhar, K., & Sharma, M. (2022). Advances in nanofabrication technology for nutraceuticals: New insights and future trends. *Bioengineering (Basel, Switzerland), 9*(9), Article 478. https://doi.org/10.3390/bioengineering9090478

30. Rambaran, T., & Schirhagl, R. (2022). Nanotechnology from lab to industry – a look at current trends. *Nanoscale Advances, 4*(18), 3664–3675. https://doi.org/10.1039/d2na00439a

31. Rodríguez-Gómez, F. D., Monferrer, D., Penon, O., & Rivera-Gil, P. (2025). Regulatory pathways and guidelines for nanotechnology-enabled health products: A comparative review of EU and US frameworks. *Frontiers in Medicine, 12*, Article 1544393. https://doi.org/10.3389/fmed.2025.1544393

32. Pal R, Pandey P, Chawra HS, Khan Z. Nano drug delivery carriers (Nanocarriers): A promising targeted strategy in tuberculosis and pain treatment. Pharmaceutical Nanotechnology. 2025 Mar 7.

33. Sindhwani, S., & Chan, W. C. W. (2021). Nanotechnology for modern medicine: Next step towards clinical translation. *Journal of Internal Medicine, 290*(3), 486–498. https://doi.org/10.1111/joim.13254

34. Singh, A. R., Desu, P. K., Nakkala, R. K., Kondi, V., Devi, S., Alam, M. S., Hamid, H., Athawale, R. B., & Kesharwani, P. (2022). Nanotechnology-based approaches applied to nutraceuticals. *Drug Delivery and Translational Research, 12*(3), 485–499. https://doi.org/10.1007/s13346-021-00960-3

35. Siri, J. G. S., Fernando, C. A. N., & De Silva, S. N. T. (2020). Nanotechnology and protection of intellectual property: Emerging trends. *Recent Patents on Nanotechnology, 14*(4), 307–327. https://doi.org/10.2174/1872210514666200612174317

36. Subcommittee on Nanoscale Science, Engineering, and Technology. (2024). *National Nanotechnology Initiative supplement to the President's 2025 budget*. National Science and Technology Council. https://www.nano.gov/sites/default/files/NNI-FY25-Budget-Supplement.pdf

37. Tamboli, F. A., Waghmare, R. S., Gajewar, S. R., Gavhane, D. G., Disale, P. P., Jogi, P. R., & Mali, U. S. (2025). Nano nutraceuticals: Revolutionizing the future of health supplements. *Biomedical and Pharmacology Journal, 18*(1). https://dx.doi.org/10.13005/bpj/3100

38. Pachani, Sachin & Shah, Tapaskumar. (2021). Formulation of Paclitaxel-Encapsulated Polymeric Micelles For Targeted Breast Cancer Therapy. Journal of Population Therapeutics and Clinical Pharmacology. 28. 936-951. 10.53555/m318xt37.

39. Towards Healthcare. (2025). *Nanomedicine market sizing and forecast 2025-2034*.

40. U.S. Food and Drug Administration. (2023, November 5). Warning letter: [Company Name] [Internet]. FDA. Available from: [insert URL if available]; cited 2025 Oct 4.

41. United Nations Institute for Training and Research. (2011). *Guidance for developing a national nanotechnology policy and programme* (Pilot ed.). https://www.nanotec.or.th/en/wp-content/uploads/2015/09/UNITAR-nano-guidance_Pilot-Edition-2011.pdf

42. Amar K, Sahoo S, Mishra R, Dutta P, Ghosh B, Pal R. Lipidic nanocarriers (liposomes): A potential targeting strategy for cosmeceutical and therapeutic applications—an in-depth review. Curr Nanomed. 2026;16:e24681873411316. doi:10.2174/0124681873411316251118051648.

43. Wang, Y., Zhang, L., & Li, X. (2023). Nanotechnology in cardiovascular therapy: Current status and future perspectives. *Biomaterials Science, 11*(4), 1123–1140.

44. World Health Organization. (2017). *WHO guidelines on protecting workers from potential risks of manufactured nanomaterials*. https://www.ncbi.nlm.nih.gov/books/NBK525054/